Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Accumulated Expenses (2016 - 2025)

Lipocine (LPCN) has disclosed Accumulated Expenses for 13 consecutive years, with $749667.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 41.99% year-over-year to $749667.0, compared with a TTM value of $749667.0 through Sep 2025, down 41.99%, and an annual FY2024 reading of $921240.0, down 24.39% over the prior year.
  • Accumulated Expenses was $749667.0 for Q3 2025 at Lipocine, up from $685779.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.6 million in Q3 2021 and bottomed at $567901.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $1.1 million, with a median of $1.1 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses soared 103.84% in 2021, then crashed 62.26% in 2022.
  • Year by year, Accumulated Expenses stood at $1.0 million in 2021, then rose by 6.03% to $1.1 million in 2022, then increased by 13.06% to $1.2 million in 2023, then fell by 24.39% to $921240.0 in 2024, then dropped by 18.62% to $749667.0 in 2025.
  • Business Quant data shows Accumulated Expenses for LPCN at $749667.0 in Q3 2025, $685779.0 in Q2 2025, and $619410.0 in Q1 2025.